Copper
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Copper: From Parenteral Trace-Element Supplementation to Esotropia
One-Sentence Summary
Copper is a trace element supplied in parenteral nutrition products. No approved indication text is recorded for it in Singapore. The TxGNN model's top prediction is esotropia, but there are no clinical trials and no publications supporting it. The best-supported alternative among the predictions is dermatitis, with 2 clinical trials (one withdrawn, one very small) and 20 publications, mostly reviews and indirect studies.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded (the Singapore licences list no approved indication text; products are trace-element infusion concentrates) |
| Predicted New Indication | Esotropia (top-ranked prediction) |
| TxGNN Prediction Score | 96.25% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 3 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, copper is an essential trace element given in parenteral nutrition, mainly to prevent or correct copper deficiency. Its mechanistic relevance to a disorder of ocular alignment is not apparent.
For esotropia, no mechanistic link between copper and the condition could be identified. The score of 0.96 comes from graph-based prediction only, with no supporting trials or literature. The prediction should be treated as a weak, unverified signal.
Of the other predictions, dermatitis is the only one with a plausible biological rationale. Copper and zinc balance is linked to skin inflammation, and preclinical work suggests that cuproptosis (copper-dependent cell death) contributes to chronic skin inflammation. However, much of the literature concerns zinc rather than copper. Copper can also act as a trigger of contact dermatitis rather than a treatment. No clinical evidence supports copper as a therapy for dermatitis. Dry eye syndrome has some preclinical support (a copper-selenide nanoparticle hydrogel), but that is a nanomaterial formulation, not copper as a marketed drug.
Clinical Trial Evidence
No clinical trials are registered for the top-ranked prediction, esotropia. The trials below relate to the second-ranked prediction, dermatitis, and are shown for context.
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT06726707 | Phase 2/3 | Withdrawn | 0 | Copper-containing absorbent incontinence products for incontinence-associated dermatitis; withdrawn, so no data |
| NCT01291628 | Not applicable | Unknown | 10 | Pilot of copper-fibre socks to prevent capecitabine-induced hand-foot syndrome; too small to support efficacy |
Literature Evidence
No publications were found for esotropia. The table below lists the most relevant publications for dermatitis, in priority order (reviews first, since no RCTs were found).
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 38612631 | 2024 | Review | Int J Mol Sci | Zinc, copper and iron imbalance in selected skin diseases; supplementation or restriction may help in dermatological treatment |
| 39102684 | 2024 | Systematic Review | JMIR Dermatol | Nutrition, obesity and nutritional supplements in seborrheic dermatitis |
| 25098945 | 2014 | Review | Contact Dermatitis | Copper hypersensitivity is infrequently reported despite wide skin exposure |
| 37331278 | 2023 | Review | J Trace Elem Med Biol | Heavy metals in contact dermatitis |
| 38367035 | 2024 | Review | Clin Exp Med | Role of zinc in health and disease (zinc-focused, not copper) |
| 41064128 | 2025 | Preclinical | MedComm | Cuproptosis promotes chronic skin inflammation via ferroptosis-related signalling |
| 38520630 | 2024 | Case report | CEN Case Rep | Copper deficiency anaemia caused by zinc supplementation in a haemodialysis patient |
| 14672513 | 2003 | Overview | Rev Environ Health | Immediate and delayed hypersensitivity reactions to copper |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN08899P | Peditrace Concentrate for Parenteral Infusion | Injection | Not recorded |
| SIN15302P | Addaven Concentrate for Solution for Infusion | Infusion, solution concentrate | Not recorded |
| SIN14341P | Nutritrace Concentrate for Solution for Infusion | Infusion, solution concentrate | Not recorded |
All three authorizations are valid single-ingredient products, and all are injectable. A new indication would need an injectable-compatible route of use.
Safety Considerations
Please refer to the package insert for safety information.
The literature compiled for this report notes that copper can cause contact hypersensitivity reactions, and that zinc supplementation can induce copper deficiency. No drug interaction records were found.
Conclusion and Next Steps
Decision: Hold
Rationale: The top prediction, esotropia, has no trials, no literature and no identifiable mechanism, so it rests on the model score alone (evidence level L5). Dermatitis is the only prediction with some indirect support (L4), but the evidence is weak: one withdrawn trial, one tiny pilot, and mostly zinc-focused or hypersensitivity-related literature. It is best treated as a research question rather than a candidate for development.
To proceed, the following is needed:
- Package insert warnings and contraindications from the Singapore regulator (currently missing and blocking safety screening)
- Mechanism of action data
- Approved indication text for the Singapore licences
- For dermatitis: controlled clinical studies showing a therapeutic benefit of copper, with clarification of whether copper is therapeutic or a trigger
- Route compatibility assessment, since the marketed products are injectables while skin or eye uses would likely need topical or ophthalmic routes
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.